Praxis Precision Medicines, Inc.
relutrigine
SCN2A and SCN8A developmental and epileptic encephalopathies
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies is in focus around Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“Assuming successful initial NDA approval of relutrigine, the EMERALD study, if positive, would serve as the basis for a supplemental NDA submission in 2027.”